Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Super Patents

Last April, both the importance and potential dangers of the coming wave of gene patents became clear when the University of Rochester was granted a patent on a gene called Cox-2. University officials immediately filed a lawsuit against G.D. Searle, a subsidiary of Pharmacia, whose blockbuster painkiller Celebrex acts by blocking the enzyme encoded by the Cox-2 gene. Rochester claims Searle’s drug infringes its patent, which describes not just the DNA letters of the gene, but also the general idea of using a drug that blocks Cox-2 as a way to alleviate pain.

The financial stakes are immense. Dubbed “super aspirin,” Cox-2 inhibitors are the hottest new pain drugs. In 1999, its first year on the market, Celebrex logged $1.5 billion in sales and eclipsed Pfizer’s potency miracle Viagra as pharmacies’ fastest-selling pill. (Merck of Whitehouse Station, N.J., also makes a Cox-2 inhibitor called Vioxx but is not named in the suit.) A University of Rochester press release giddily predicted the university’s patent is “likely to be the most lucrative in U.S. history.”

The case highlights several troubling aspects of gene patenting. As a tactic to pressure Searle into paying royalties, Rochester has asked a judge to force the company to take the drug off the market, despite the fact that it is used by nearly seven million people, many of whom suffer from severe arthritis. The case also raises new and difficult questions about what a patentable ” invention” really is. Is it Celebrex, a drug developed by industry at a cost of millions of dollars? Or is it the knowledge of Cox-2’s role in pain and inflammation, a fundamental scientific discovery paid for with federal research monies?

Gerald Dodson, a litigator Rochester has hired from the firm Morrison & Foerster, says, “If you discover something that opens a new area of research, then it should be patentable. That is what’s at the heart of this. Somehow there is a school of thought that different rules should apply to basic research in medicine, and I don’t think that washes under any kind of scrutiny. “

Searle freely admits it used scientific findings about Cox-2 as the starting point for its hunt for a drug. (The Cox-2 discovery has also prompted drug research aimed at treatments for Alzheimer’s disease and cancer.) But Searle lawyers say the Rochester patent is invalid because it doesn’t give precise enough directions for finding a drug. In the parlance of patent law, Rochester’s claim qualifies as a classic “submarine patent”: a broad early claim that quietly sits at the Patent Office only to surface when another inventor’s work gives it commercial significance.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me